检索结果 - Aniruddha Amrite
- Showing 1 - 5 results of 5
-
1
-
2
-
3
-
4
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria 由 Bernd Höppe, Annelize Koch, Pierre Cochat, Sander F. Garrelfs, Michelle A. Baum, Jaap W. Groothoff, Graham Lipkin, Martin Coenen, Gesa Schalk, Aniruddha Amrite, David McDougall, Kelly Barrios, Craig B. Langman
出版 2021Artigo -
5
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2 由 Michelle A. Baum, Craig B. Langman, Pierre Cochat, John C. Lieske, Shabbir H. Moochhala, Shuzo Hamamoto, Hiroyuki Satoh, Chebl Mourani, Gema Ariceta, Armando Torres, Martin Wolley, Vladimir Belostotsky, Thomas Forbes, Jaap W. Groothoff, Wesley Hayes, Burkhard Tönshoff, Tatsuya Takayama, R. Roßkamp, Kerry Russell, Jing Zhou, Aniruddha Amrite, Bernd Höppe
出版 2022Artigo
相关主题
Medicine
Chemistry
Endocrinology
Internal medicine
Pharmacology
Biochemistry
Excretion
Kidney
Ophthalmology
Organic chemistry
Oxalate
Pharmacokinetics
Primary hyperoxaluria
Alternative medicine
Celecoxib
Clinical endpoint
Cornea
Diabetes mellitus
Diabetic retinopathy
Dosing
Drug delivery
Gastroenterology
Gene
Gene delivery
Genetic enhancement
In vitro
Materials science
Nanocarriers
Nanomedicine
Nanoparticle